SHANGHAI, Jan 27 (Reuters) – China’s drug regulator has ordered a halt to the import, sale and use of a drug made by India’s Sun Pharmaceutical Industries Ltd to treat Alzheimer’s-related dementia, according to an announcement on Monday.
The National Medical Products Administration said a recent remote inspection found deficiencies in the company’s production process in areas such as pollution prevention and quality management department performance.
The agency banned the sale of Sun Pharma’s rivastigmine tartrate hydrogen capsules.
A spokesman for Sun Pharma, India’s largest drugmaker by revenue, did not immediately respond to a request for comment.
In 2024, the U.S. Food and Drug Administration issued a warning letter to Sun Pharma, accusing it of “serious violations” of “current good manufacturing practice” regulations for drugs produced at the same manufacturing site in India, according to the U.S. regulator’s website.
Rivastigmine capsules have been used to treat dementia in China, according to a study.
(Reporting by Andrew Silver; Editing by Thomas Deppinghaus)